RxDoctor Payments Data

Michael Stojanovic, MD

Orthopaedic Surgery · Omaha, NENPI 1831586866

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (46.3%), education and travel and lodging — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Stryker at 46.5% of the total. Reporting peaked in 2022 at $8,375 and has fallen 88.6% since, to $954 in 2025.

$22,262in general payments, 2019–2025

Across 167 payments — averaging $133.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$10K
  • Smith+Nephew$6K
  • Medical Device Business Services, Inc.$2K
  • Gemini Medical LLC$2K
  • Johnson & Johnson$1K
  • Medtronic$1K
  • plus $208 from 4 others

What the payments were for

  • Consulting fees$9304%
  • Travel & lodging$3,18814%
  • Food & beverage$10,31446%
  • Education$7,83035%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,262 in reported general payments places this provider in the 85th percentile of 155 orthopaedic surgery providers in Nebraska.

See all orthopaedic surgery providers in Nebraska

Medicare billing

Part B allowed, 2024
$189,020
Medicare patients
363
Services billed
13,783

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Meloxicam178$402
Methylprednisolone28$223
Celecoxib11$167
Tramadol Hcl30$104
Oxycodone Hcl12$68
Amoxicillin11$11

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →